Immucor is dedicated to offering products that enable patients anywhere who are in need of blood or an organ to receive the right match that is safe, accessible and affordable. The result is life changing for a patient in need of a transfusion or transplant. Immucor is a leading provider of transfusion and transplantation diagnostic products worldwide. Our new corporate identity illustrates the right match of donors with patients in need of blood or an organ as well as Immucor’s partnership with healthcare organizations in need of innovation and productivity.
Company Growth (employees)
Type
Private
HQ
Norcross, US
Founded
1982
Size (employees)
901 (est)
Immucor was founded in 1982 and is headquartered in Norcross, US

Immucor Office Locations

Immucor has an office in Norcross
Norcross, US (HQ)
3130 Gateway Dr

Immucor Data and Metrics

Summary Metrics

Founding Date

1982

Immucor Financial Metrics

Immucor's revenue was reported to be $94 m in Q3, 2017
USD

Revenue (Q3, 2017)

94 m

Gross profit (Q3, 2017)

94 m

Gross profit margin (Q3, 2017), %

100%

Net income (Q3, 2017)

(32.3 m)

EBIT (Q3, 2017)

8.1 m

Cash (28-Feb-2017)

10 m
USDFY, 2016

Revenue

380 m

Cost of goods sold

144 m

Gross profit

236 m

Gross profit Margin, %

62%

R&D expense

30.3 m

General and administrative expense

44.5 m

Operating expense total

207.1 m

EBIT

28.9 m

EBIT margin, %

8%

Interest expense

(90.5 m)

Interest income

135 k

Pre tax profit

(61.7 m)

Income tax expense

(18 m)

Net Income

(43.8 m)
USDQ1, 2014Q2, 2014Q3, 2015Q1, 2015Q2, 2015Q3, 2016Q1, 2016Q2, 2016Q3, 2017

Revenue

102.4 m96.3 m95.6 m96.7 m96.2 m88.9 m98.6 m93.7 m94 m

Cost of goods sold

36.8 m35.8 m34 m34.6 m37.9 m34.1 m38.2 m

Gross profit

65.6 m60.5 m61.6 m62.1 m58.4 m54.8 m98.6 m55.5 m94 m

Gross profit Margin, %

64%63%64%64%61%62%100%59%100%

R&D expense

7.1 m7.1 m7.3 m6.8 m6.8 m6.9 m9 m8.8 m8.8 m

General and administrative expense

10.9 m10.7 m9.4 m10.7 m10.6 m11.8 m11.6 m10.5 m10 m

Operating expense total

18 m17.8 m16.6 m17.6 m17.4 m18.7 m20.5 m19.3 m18.9 m

EBIT

13.9 m8.4 m12.9 m12.5 m8.2 m5.1 m8.2 m2.2 m8.1 m

EBIT margin, %

14%9%13%13%9%6%8%2%9%

Interest expense

(22.3 m)(22.8 m)(21.8 m)(22.5 m)(22.5 m)(22.3 m)(23.1 m)(23.1 m)(23 m)

Interest income

56 k32 k42 k42 k41 k48 k6 k8 k1 k

Pre tax profit

(8.3 m)(14.2 m)(8.7 m)(10.1 m)(14.1 m)(17.5 m)(15.5 m)(20.9 m)(15 m)

Income tax expense

(2.8 m)(5.1 m)(2.9 m)(2.4 m)(8.8 m)(5.4 m)(8.1 m)(5.6 m)

Net Income

(5.5 m)(14.6 m)(54 m)(7.2 m)(19 m)(27.7 m)(10.1 m)(22.9 m)(32.3 m)
USDFY, 2014FY, 2015FY, 2016

Cash

23.6 m18.4 m10.3 m

Accounts Receivable

62 m

Inventories

49.2 m11.2 m46.9 m

Current Assets

163.2 m145 m127.7 m

PP&E

76.3 m73.6 m76 m

Goodwill

851.6 m842.3 m857 m

Total Assets

1.8 b1.8 b1.7 b

Accounts Payable

15.7 m13.9 m22.2 m

Total Debt

6.8 m

Current Liabilities

71.3 m70 m75.4 m

Total Liabilities

1.4 b

Additional Paid-in Capital

753.1 m755.2 m753.7 m

Retained Earnings

(271.3 m)(332 m)(374.1 m)

Total Equity

468.6 m383.7 m344.5 m

Debt to Equity Ratio

0 x

Debt to Assets Ratio

0 x

Financial Leverage

3.9 x4.6 x5 x
USDQ1, 2015Q2, 2015Q3, 2016Q1, 2016Q2, 2016Q3, 2017

Cash

19 m15.1 m12.2 m9.7 m10.5 m10 m

Inventories

48.5 m44.7 m47.8 m49.3 m47.3 m48.9 m

Current Assets

149.3 m140.6 m135.8 m133.2 m125.3 m131.9 m

PP&E

73.3 m72.2 m72.8 m75.9 m76.3 m76.8 m

Goodwill

842.3 m840.5 m840.8 m856.7 m854.4 m854.7 m

Total Assets

1.7 b1.7 b1.7 b1.7 b1.7 b1.7 b

Accounts Payable

16 m13.7 m17.6 m18 m17.4 m21.3 m

Current Liabilities

69.9 m60.8 m59.5 m79.7 m80.7 m85.9 m

Additional Paid-in Capital

756.1 m758 m753.3 m754.6 m752.2 m750 m

Retained Earnings

(339.2 m)(351 m)(359.4 m)(382.7 m)(394 m)(401.7 m)

Total Equity

377.4 m362.1 m356.6 m336.1 m317.9 m310.4 m

Financial Leverage

4.6 x4.7 x4.8 x5.1 x5.3 x5.4 x
USDFY, 2014FY, 2015FY, 2016

Net Income

(6.4 m)(60.7 m)(43.8 m)

Depreciation and Amortization

50.8 m50.8 m54.9 m

Inventories

(3.1 m)(12 m)

Accounts Payable

(1.4 m)8.3 m

Cash From Operating Activities

25.6 m27.1 m

Purchases of PP&E

(11.4 m)(9.9 m)

Long-term Borrowings

(6.7 m)(6.7 m)

Interest Paid

79.2 m78.8 m

Income Taxes Paid

111 k(160 k)
USDQ1, 2014Q2, 2014Q3, 2015Q1, 2015Q2, 2015Q3, 2016Q1, 2016Q2, 2016Q3, 2017

Net Income

(5.5 m)(14.6 m)(54 m)(7.2 m)(19 m)(27.7 m)(10.1 m)(22.9 m)(32.3 m)

Depreciation and Amortization

18.4 m36.1 m53.8 m17 m34.2 m51.4 m18.2 m36.2 m54.1 m

Inventories

(1.8 m)(2.4 m)(6 m)(7.9 m)(6.2 m)(11 m)(3.9 m)(4.1 m)(8.3 m)

Accounts Payable

2.1 m2.7 m(3.3 m)2.2 m(187 k)4.2 m(4.1 m)(4.3 m)(779 k)

Cash From Operating Activities

15 m2.8 m8 m6.8 m974 k

Purchases of PP&E

(3.3 m)(6.9 m)(7.5 m)(2 m)(3.9 m)(7.1 m)(2.8 m)(6.9 m)(8.2 m)

Long-term Borrowings

(1.7 m)(3.3 m)(5 m)(1.7 m)(3.3 m)(5 m)(1.7 m)(3.4 m)(5.1 m)

Dividends Paid

(4.5 m)(7.7 m)

Cash From Financing Activities

19.3 m

Interest Paid

30.5 m39.7 m70.7 m30.8 m39.5 m70.3 m30.7 m39.3 m69.9 m

Income Taxes Paid

71 k(25 k)526 k300 k(309 k)(495 k)481 k988 k695 k
USDY, 2017

Revenue/Employee

107.8 k

Financial Leverage

5.4 x

Immucor Online and Social Media Presence

Immucor Company Life and Culture

You may also be interested in